NCT00278902View on ClinicalTrials.gov

A Study of ARRY-334543 in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Advanced Cancer
Interventions
DRUG

ARRY-334543, EGFR/ErbB2 inhibitor; oral

Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule

Trial Locations (5)

19111

Fox Chase Cancer Center, Philadelphia

37203

Sarah Cannon Research Center, Nashville

37232

Vanderbilt University Medical Center, Nashville

V1Y 5L3

British Columbia Cancer Agency- Centre for the Southern Interior, Kelowna

V5Z 4E6

British Columbia Cancer Agency, Vancouver

All Listed Sponsors
lead

Array Biopharma, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00278902 - A Study of ARRY-334543 in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter